Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / news releases / HLTRF - HLS Therapeutics to Host Q1 2020 Financial Results Conference Call


HLTRF - HLS Therapeutics to Host Q1 2020 Financial Results Conference Call

Canada NewsWire

TORONTO, April 30, 2020

TORONTO, April 30, 2020 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 2020 financial results by press release at 6:30 a.m. Eastern Time on Thursday, May 7, 2020. The Company will hold a conference call that same day at 8:30 a.m. Eastern Time to discuss its results. The call will be hosted by Mr. Greg Gubitz, Chief Executive Officer, Mr. Gilbert Godin, President and Chief Operating Officer and Mr. Tim Hendrickson, Chief Financial Officer. To participate on the call, please enter a dial-in number below and then enter the Conference ID when prompted.

CONFERENCE ID:

6457646



DATE:

Thursday, May 7, 2020



TIME:

8:30 a.m. Eastern Time



DIAL-IN NUMBER:

1-877-267-7318 or 631-485-5848



WEBCAST LINK:

https://produceredition.webcasts.com/starthere.jspei=1311902&tp_key=59c36737e9 



TAPED REPLAY:

1-855-859-2056 or 404-537-3406



REPLAY CODE:

6457646

 

The taped replay will be available for 14 days and the archived webcast will be available for 90 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

SOURCE HLS Therapeutics Inc.

View original content: http://www.newswire.ca/en/releases/archive/April2020/30/c8370.html

Dave Mason, Investor Relations, HLS Therapeutics Inc., (416) 247-9652, dave.mason@loderockadvisors.com; Gilbert Godin, President and Chief Operating Officer, HLS Therapeutics Inc., (484) 232-3400 ext101, g.godin@hlstherapeutics.comCopyright CNW Group 2020

Stock Information

Company Name: HLS Therapeutics Inc
Stock Symbol: HLTRF
Market: OTC
Website: hlstherapeutics.com

Menu

HLTRF HLTRF Quote HLTRF Short HLTRF News HLTRF Articles HLTRF Message Board
Get HLTRF Alerts

News, Short Squeeze, Breakout and More Instantly...